1,2 In a recently published report, Cools et al 3 described response in nine of 11 HES patients treated with imatinib. In five of these nine patients, fusion of the Fip1-like1 (FIP1L1) gene to the PDGFR alpha (PDGFRA) gene was detected, leading to expression of an activated tyrosine kinase that is thought to be a target of imatinib. We report here a case of a leukemic form of HES refractory to intensive treatment (including allograft) in whom sustained clinical and molecular response was induced by imatinib.
A 29-year-old male patient presented in November 1998 with weight loss, night sweats, myalgias, and diarrhea. Splenomegaly was noted on physical examination and the blood count showed WBC 72.6 Â 10 9 /l (62% eosinophils), platelets 799 Â 10 9 /l, and hemoglobin 114 g/l. Bone marrow biopsy revealed extensive eosinophilic infiltration (56%) with reticulinic fibrosis. Computerized axial tomographic scan confirmed massive splenomegaly without adenopathy. Chromosomal analysis was normal and fluorescence in situ hybridization for BCR-ABL was negative. Splenectomy was performed and histological examination of the spleen showed myeloid proliferation. Molecular genetic analyses showed no evidence of a monoclonal T-cell or B-cell population. From November 1998 to June 2000, the patient failed to respond to successive treatments including: (1) hydroxyurea 1500 mg/day þ prednisone 40 mg/day; (2) interferon alpha (5 MUI/day) þ cytarabine (20 mg/m 2 /day) 10 days/ month), and (3) thiotepa (100 mg) þ etoposide (150 mg) day 1 and day 15 monthly. In June 2000, a subcutaneous pectoral tumor appeared and the patient's general condition worsened. At this stage, the eosinophil count was 14.6 Â 10 9 /l. An ABDR HLA-mismatched (4/6) cord blood allograft (0.12 Â 10 4 CFU-GM/kg of body recipient) was performed in July 2000 after cyclophosphamide and total body irradiation conditioning regimen. After 2 months, eosinophilia persisted (11.2 Â 10 9 /l) and the patient was cachetic secondary to diarrhea. Palliative treatment (low doses of thiotepa and etoposide monthly) was started and by May 2002, the eosinophil count was 7.6 Â 10 9 /l, but there was further worsening of clinical status. Then, Imatinib (200 mg/day) was started. After 15 days of treatment, complete clinical response, normal biological and blood count and marrow were achieved which persisted 1 year later. Using the technique reported by Cools et al, we demonstrated FIP1L1-PDGFRA fusion transcript in this patient at the time of diagnosis (November 98) and loss of this transcript in repeated testing carried out in May 2003, 1 year after the initiation of Imatinib treatment (Figure 1a) . Good RNA quality of the samples were validated using ABL housekeeping gene and quantified using EAC recommendations. 6 However, the sensitivity of the technique performed on cDNA dilutions from diagnosis in CEM cell line cDNA was very low (10-3 after the second round). Direct sequencing of the PCR product identified a novel fusion transcript between FIP1L1 exon 8a and PDGFRA exon 12 (Figure 1b) .
HES with myeloproliferative features carry a poor prognosis and has no widely accepted treatment. High-dose chemotherapy has been proposed for the treatment of very aggressive forms. 1, 4, 5 The case reported here illustrates that even after failure of very intensive treatment, rapid and sustained molecular response can be achieved using imatinib therapy. Analysis of the FIP1L1-PDGFRA fusion transcript appears very helpful in HES, in order to identify patients with FIP1L1-PDGFRA fusion transcripts with a high probability of responding 
